NKGen Biotech, Inc. (“NKGen” or the “Company”) has regained compliance on its public reporting obligations with the filing of its most recent quarterly report on Form 10-Q on March 4, 2025; and ...

“This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive ...

Retrouvés dans le cerveau humain, mais aussi dans les intestins des nourrissons, les microplastiques peuvent entraîner des ...

Génération de Trésorerie (« Cash Flow ») avant financement de 15,0 millions d’euros, en progression comparé aux (132,2) millions d’euros de 2023, sous l'effet d'une gestion rigoureuse des stocks ...

The webcast of the fireside chat will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.

Leerink Global Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside ...

Simultaneous expansion and activation of both major γδ T cell subsets (Vδ1+ and Vδ2+) leverages both the rapid antigen presenting properties of Vδ2+ T cells and the longer-term resistance against ...

To request a meeting, please contact your ROTH sales representative. About Synergy CHC Corp.

PHILADELPHIA, March 03, 2025 (GLOBE NEWSWIRE) -- Instinct Science, a leader in veterinary software innovation, announces the launch of Standards of Care™ (standards.vet), a next-generation clinical ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a ...

Operating Income was € (120.4) million compared to € (234.3) million in 2023. Financial income was € (19.2) million, compared with € (8.5) million in 2023, due to the increase in interest rates and ...

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, ...